Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc. announced the appointment of Paul Lyne, Ph.D., as its new Chief Science Officer. Concurrently, co-founder and long-time CSO, Michael K. Schultz, Ph.D., has transitioned to the role of Senior Scientific Advisor & Co-Founder as part of a planned retirement. The company expects Dr. Lyne's extensive experience in oncology research and drug development to accelerate its scientific strategy and pipeline advancement, while Dr. Schultz's continued advisory role will ensure ongoing scientific guidance.

Perspective Therapeutics, Inc. updated its corporate presentation, detailing its strategy to redefine oncology treatment with next-generation radiopharmaceuticals. The presentation highlighted the advancement of its diverse 212Pb-based oncology portfolio, including positive Phase 1/2a data for VMT-α-NET in neuroendocrine tumors and initial anti-tumor activity for VMT01 in melanoma. The company also emphasized its integrated isotope production for direct-to-hospital delivery and a strong intellectual property portfolio.

Perspective Therapeutics announced that the first meningioma patient has been dosed with [212Pb]VMT-α-NET in its ongoing Phase 1/2a study. This new cohort, named LEMONαDE, aims to assess the safety, dosimetry, and preliminary anti-tumor activity of the lead-based alpha-particle therapy for meningioma, reflecting the company's strategy to expand evaluation beyond neuroendocrine tumors. Meningiomas are the most common primary brain tumors, often presenting limited treatment options for recurrent or unresectable cases, making them an attractive target due to consistent SSTR2 expression.

Perspective Therapeutics announced positive interim results from its ongoing clinical trials for [212Pb]VMT01, [212Pb]PSV359, and [212Pb]VMT-α-NET, which will be presented at the 2026 ASCO Annual Meeting. The [212Pb]VMT01 melanoma trial observed a new responder, bringing total confirmed responses to 29% in the 3.0 mCi monotherapy cohort, with 86% showing stable disease or partial response. All three programs demonstrated good tolerability and safety profiles, with [212Pb]PSV359 advancing to Cohort 3 and [212Pb]VMT-α-NET showing continued deepening of responses and 72% of patients without progression.

Perspective Therapeutics announced positive updates on all three of its clinical programs, [²¹²Pb]VMT-α-NET, [²¹²Pb]VMT01, and [²¹²Pb]PSV359, which will be presented at the 2026 ASCO Annual Meeting. The [²¹²Pb]VMT01 melanoma study observed a new responder, bringing the total to two confirmed responses out of seven treated patients (29%) in the monotherapy cohort, with 86% showing stable disease or partial response. Updated data for [²¹²Pb]VMT-α-NET in neuroendocrine tumors showed continued deepening of responses and 72% of patients without progression, while [²¹²Pb]PSV359 advanced to Cohort 3 for solid tumors, with all programs demonstrating good tolerability.

Perspective Therapeutics announced that the first patients were dosed in new cohorts for two of its Phase 1/2a clinical trials. The fourth cohort of the [212Pb]VMT-α-NET trial for neuroendocrine tumors will explore a front-loading dosing regimen to optimize response kinetics and improve efficacy. Additionally, the third cohort of the [212Pb]PSV359 trial for solid tumors has begun dosing after a safety review, aiming to assess safety and preliminary anti-tumor activity.

Perspective Therapeutics, Inc. reported a net loss of $(26.2) million for the first quarter of 2026, an increase from $(18.2) million in the same period last year. Despite the increased loss, the company significantly bolstered its financial position by closing an underwritten offering in February 2026, which generated approximately $175.0 million in gross proceeds. As a result, cash, cash equivalents, and short-term investments stood at $270.9 million as of March 31, 2026, which management believes will fund operations into late 2027.

Perspective Therapeutics, Inc. reported a business update and Q1 2026 financial results, showing a net loss of $26.2 million. The company significantly strengthened its financial position with cash, cash equivalents, and short-term investments totaling $271 million as of March 31, 2026, following a $164 million underwritten offering in February. This provides a cash runway into late 2027 to support planned clinical milestones and operational investments. The company also highlighted continued progress across its three clinical-stage oncology programs and expansion of its manufacturing infrastructure, with multiple clinical catalysts anticipated in 2026.

Perspective Therapeutics, Inc. posted a presentation to its website, detailing updates from an analyst event. The presentation highlighted advancements in its clinical programs, including the VMT-α-NET for neuroendocrine tumors, which showed durable disease control in an ongoing Phase 1/2a study. The company also provided insights into its 212Pb-based radiopharmaceutical pipeline, manufacturing technologies, and integrated isotope production capabilities. The filing also noted preliminary estimated cash, cash equivalents, and short-term investments as of March 31, 2026, which are unaudited.

Perspective Therapeutics announced a series of corporate updates and investor events scheduled for May 2026. These include an analyst event on May 4th to discuss strategy and pipeline, the release of First Quarter 2026 financial results on May 11th, and participation in two major healthcare conferences on May 13th and May 19th. These events aim to provide insights into the company's progress and future direction.